Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05199012
Other study ID # #21-CAHS-103
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 15, 2021
Est. completion date December 15, 2022

Study information

Verified date September 2023
Source The Center for Applied Health Sciences, LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a randomized, placebo-controlled, double-blind, two-arm trial of N=94 apparently healthy men and women to be recruited at a single investigational center in Northeast Ohio. Subjects will attend three study visits. During Visit 1, subjects will be screened for participation (i.e., medical history, physical exam, routine blood work, background baseline diet). Over the next 12 weeks, subjects will attend Visits 2 (baseline) and 3 (week 12), wherein assessments of body weight, waist circumference, urinary ketones, serum glucose, insulin, liver enzymes as well as other biomarkers of metabolic health, quality of life (SF-36 questionnaire), and various visual analog scales (VAS) for appetite, satiety, and cravings will be made.


Recruitment information / eligibility

Status Completed
Enrollment 86
Est. completion date December 15, 2022
Est. primary completion date December 15, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years to 65 Years
Eligibility Inclusion Criteria: - Provide voluntary signed and dated informed consent. - Be in good health as determined by medical history and routine blood chemistries. - Age between the ages of 21 and 65 (inclusive). - Body Mass Index of 25-34.99 (inclusive). - Body weight of at least 120 pounds. - Normotensive (seated, resting systolic blood pressure <140 mm Hg and diastolic blood pressure < 90 mm Hg. If the first measurement is slightly elevated above these limits, the subject will be given a brief (5 minute) rest period, and two more measurements will be taken. The average of all three measurements will be used to determine eligibility. - Normal seated, resting heart rate (<90 per minute). - Willing to duplicate their previous 24-hour diet, refrain from caffeine for 12 hr, abstain from exercise for 24 hr, and fast for 10 hours prior to each laboratory visit. Exclusion Criteria: - History of unstable or new-onset cardiovascular or cardiorespiratory disease. - Individuals diagnosed with diabetes or other endocrine disorder. - Fasting blood sugar of > 126 mg/dL OR HgA1c of > 6.5%. - History of use of medications or dietary supplements known to affect glycemia or insulinemia. - Current use of amiodarone, anti-retroviral agents, corticosteroids, methotrexate, tamoxifen, valproate, amitriptyline (Elavil), codeine, desipramine (Norpramin), flecainide (Tambocor), haloperidol (Haldol), imipramine (Tofranil), metoprolol (Lopressor, Toprol XL), ondansetron (Zofran), paroxetine (Paxil), risperidone (Risperdal), tramadol (Ultram), venlafaxine (Effexor), cyclosporine, lithium, chlorzoxazone, theophylline, and bufuralol, cyclophosphamide, ifosfamide, barbiturates, bromobenzene, lovastatin (Mevacor), ketoconazole (Nizoral), itraconazole (Sporanox), fexofenadine (Allegra), triazolam (Halcion), glimepiride (Amaryl), glyburide (DiaBeta, Glynase PresTab, Micronase), insulin, pioglitazone (Actos), rosiglitazone (Avandia), etoposide, paclitaxel, vinblastine, vincristine, vindesine, amprenavir, indinavir, nelfinavir, saquinavir, cimetidine, ranitidine, diltiazem, verapamil, digoxin, erythromycin, cisapride (Propulsid),, loperamide (Imodium), quinidine, aspirin, clopidogrel (Plavix), dalteparin (Fragmin), enoxaparin (Lovenox), heparin, ticlopidine (Ticlid), warfarin (Coumadin), nevirapine, Pentobarbital (Nembutal), Phenytoin (Dilantin), Propranolol (Inderal), Rifampin, Amoxicillin (Amoxil, Trimox), Carbamazepine (Tegretol), Cefotaxime (Claforan), midazolam, diclofenac. - History of hyperparathyroidism or an untreated thyroid disease. - History of nephrotic syndrome or renal disease. - History of alcohol abuse within the past year. - History of malignancy in the previous 5 years except for non-melanoma skin cancer (basal cell cancer or squamous cell cancer of the skin). - Prior gastrointestinal bypass surgery (Lapband), etc. - Other known gastrointestinal or metabolic diseases that might impact nutrient absorption or metabolism, e.g., short bowel syndrome, diarrheal illnesses, history of colon resection, gastro paresis, Inborn-Errors-of-Metabolism (such as PKU). - Chronic inflammatory condition or autoimmune disease (e.g., rheumatoid arthritis, hepatitis, Crohn's disease, ulcerative colitis, Lupus, HIV/AIDS, etc.). - Female subjects who are pregnant, trying to become pregnant, or lactating. Women who participate in this study must agree to the use of contraception for the duration of the study and any woman that is sexually active will have to have a negative pregnancy test prior to enrolling. Women of childbearing age (any woman prior to menopause or surgically sterilized) regardless of their use of contraception will be provided a urine pregnancy test kit at their screening visit and take the test in private using the female lavatory after signing an informed consent. - Known sensitivity to any ingredient in the test formulations as listed in the Certificates-of- Analysis. - Currently participating in another research study with an investigational product or have been in another research study in the past 30 days. - Any other diseases or conditions that, in the opinion of the medical staff, could confound the primary endpoints or place the subject at increased risk of harm if they were to participate.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Black pepper extract
Subjects will be randomized to receive either the placebo or active (black pepper extract) in a 1:1

Locations

Country Name City State
United States The Center for Applied Health Sciences Canfield Ohio

Sponsors (2)

Lead Sponsor Collaborator
The Center for Applied Health Sciences, LLC Brightseed, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Appetite appetite as measured with a 10 cm anchored visual analogue scale, where higher values represent greater cravings. Change from baseline to week 12
Other Satiety satiety as measured with a 10 cm anchored visual analogue scale, where higher values represent greater satiety. Change from baseline to week 12
Other Cravings cravings as measured with a 10 cm anchored visual analogue scale, where higher values represent greater cravings. Change from baseline to week 12
Other Short Form Health Survey (SF-36) health status as measured with the SF-36 questionnaire, where scores range from 0 to 100, and higher values represent better health status. Chnage from baseline to week 12
Primary waist circumference measurement of waist circumference in centimeters Change from baseline to week 12
Primary triglycerides measurement of triglycerides in blood Change from baseline to week 12
Secondary urinary ketones ketone concentration in urine Change from baseline to week 12
Secondary plasma free fatty acids concentration of free fatty acids in plasma Change from baseline to week 12
Secondary body weight body weight measurement in kg Change from baseline to week 12
Secondary Body mass index body mass index (body weight relative to height) Change from baseline to week 12
Secondary liver enzymes fasting levels of ALT and AST measured in international units per liter (IU/L) Change from baseline to week 12
See also
  Status Clinical Trial Phase
Recruiting NCT03995979 - Inflammation and Protein Restriction N/A
Completed NCT03255187 - Effect of Dietary Supplemental Fish Oil in Alleviating Health Hazards Associated With Air Pollution N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT03577223 - Egg Effects on the Immunomodulatory Properties of HDL N/A
Completed NCT04383561 - Relationship Between LRG and Periodontal Disease N/A
Active, not recruiting NCT03622632 - Pilot Study to Measure Uric Acid in Traumatized Patients: Determinants and Prognostic Association
Completed NCT06216015 - Exercise Training and Kidney Transplantation N/A
Completed NCT04856748 - Nomogram to Diagnose Prostatic Inflammation (PIN) in Men With Lower Urinary Tract Symptoms
Completed NCT05529693 - Efficacy of a Probiotic Strain on Level of Markers of Inflammation in an Elderly Population N/A
Recruiting NCT05670301 - Flemish Joint Effort for Biomarker pRofiling in Inflammatory Systemic Diseases N/A
Recruiting NCT05415397 - Treating Immuno-metabolic Depression With Anti-inflammatory Drugs Phase 3
Recruiting NCT04543877 - WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study Early Phase 1
Recruiting NCT05775731 - Markers of Inflammation and of the Pro-thrombotic State in Hospital Shift and Day Workers
Completed NCT03859934 - Metabolic Effects of Melatonin Treatment Phase 1
Completed NCT03429920 - Effect of Fermented Soy Based Product on Cardiometabolic Risk Factors N/A
Active, not recruiting NCT06065241 - Quantifiably Determine if the Botanical Formulation, LLP-01, Has a Significant Clinical Effect on Proteomic Inflammatory Biomarkers and Epigenetic Changes in Healthy, Older Individuals. N/A
Active, not recruiting NCT05864352 - The Role of Dietary Titanium Dioxide on the Human Gut Microbiome and Health
Completed NCT03318731 - Efficacy and Safety of Fenugreek Extract on Markers of Muscle Damage and Inflammation in Untrained Males N/A
Not yet recruiting NCT06134076 - Comparing Effects of Fermented and Unfermented Pulses and Gut Microbiota N/A
Not yet recruiting NCT05910489 - Micro and Nanoplastics in Greenhouse Workers: Biomarkers of Exposure and Effect